These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 33844056)

  • 1. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    Centonze D; Rocca MA; Gasperini C; Kappos L; Hartung HP; Magyari M; Oreja-Guevara C; Trojano M; Wiendl H; Filippi M
    J Neurol; 2021 Nov; 268(11):3961-3968. PubMed ID: 33844056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
    Costa Frossard-França L; García-Domínguez JM; Moreno-Torres I; Fortún J; Villar LM; Meca-Lallana V
    Rev Neurol; 2021 Apr; 72(7):250-260. PubMed ID: 33764494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.
    Pugliatti M; Berger T; Hartung HP; Oreja-Guevara C; Bar-Or A
    Curr Opin Neurol; 2022 Jun; 35(3):319-327. PubMed ID: 35674075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.
    Pugliatti M; Hartung HP; Oreja-Guevara C; Pozzilli C; Airas L; Alkhawajah M; Grigoriadis N; Magyari M; Van Wijmeersch B; Zakaria M; Linker R; Chan A; Vermersch P; Berger T
    Front Immunol; 2022; 13():1045101. PubMed ID: 36325318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.
    Chirap-Mitulschi IA; Ghimus C; Chirap-Mitulschi AR; Antoniu SA; Dragomir R
    Drugs Today (Barc); 2022 Dec; 58(12):605-620. PubMed ID: 36651068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study.
    Heidler F; Baldt J; Frahm N; Langhorst SE; Mashhadiakbar P; Streckenbach B; Zettl UK; Richter J
    Eur Neurol; 2022; 85(2):104-111. PubMed ID: 34743082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis.
    Woopen C; Schleußner K; Akgün K; Ziemssen T
    Front Immunol; 2021; 12():701752. PubMed ID: 34234787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.
    Pernicová E; Macounová P; Krsek M; Maďar R
    Eur Neurol; 2023; 86(4):263-276. PubMed ID: 36871554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
    Stoll S; Desai S; Levit E
    Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
    Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
    Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.
    Bilge N; Kesmez Can F; Yevgi R
    Acta Neurol Belg; 2023 Oct; 123(5):1885-1892. PubMed ID: 36331727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
    Smith JB; Gonzales EG; Li BH; Langer-Gould A
    JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of MS disease-modifying therapies on responses to vaccinations: A review.
    Ciotti JR; Valtcheva MV; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102439. PubMed ID: 32769063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
    Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
    Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Vaccine Response in People with Multiple Sclerosis.
    Tallantyre EC; Vickaryous N; Anderson V; Asardag AN; Baker D; Bestwick J; Bramhall K; Chance R; Evangelou N; George K; Giovannoni G; Godkin A; Grant L; Harding KE; Hibbert A; Ingram G; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Schmierer K; Scurr MJ; Shah SN; Simmons J; Upcott M; Willis M; Jolles S; Dobson R
    Ann Neurol; 2022 Jan; 91(1):89-100. PubMed ID: 34687063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine hesitancy among people with multiple sclerosis.
    Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
    Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.